Research
Conferences & Presentations
OBRI researchers present findings at leading national and international rheumatology conferences, contributing to the global conversation on real-world arthritis evidence.
2026
CRA 2026
Defining Difficult-to-Treat Rheumatoid Arthritis in Routine Care: Comparative Performance of Published Criteria and Description of Early and Late D2T-RA Phenotypes
Attar R, Movahedi M, Cesta A, Akhavan P, Thorne C, Pope J, Kwok T, Lau A, Mirza R, Hepworth E, Chow A, Kuriya B, Aydin S, on behalf of OBRI Investigators.
Baseline Predictors of Difficult-To-Treat Rheumatoid Arthritis Across Adapted Definitions: Insights from the OBRI-RA Registry
Attar R, Movahedi M, Cesta A, Akhavan P, Thorne C, Pope J, Kwok T, Lau A, Mirza R, Hepworth E, Chow A, Kuriya B, Aydin S, OBRI Investigators.
EULAR 2026
Impact of Coexisting Gout on Disease Activity in Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)
Kwok T, Movahedi M, Cesta A, Akhavan P, Thorne C, Pope J, Lau A, Mirza R, Hepworth E, Chow A, Aydin S, Kuriya B.
Defining Difficult-to-Treat Rheumatoid Arthritis in Routine Care: Comparative Performance of Published Criteria and Description of Early and Late D2T-RA Phenotypes
Attar R, Movahedi M, Cesta A, Akhavan P, Thorne C, Pope J, Kwok T, Lau A, Mirza R, Hepworth E, Chow A, Kuriya B, Aydin S, OBRI Investigators.
Cardiorenal–Metabolic Comorbidity and Therapy Eligibility in Rheumatoid Arthritis: Real-World Data from the OBRI
Movahedi M, Seebalack V, Cesta A, Akhavan P, Thorne C, Pope J, Kwok T, Lau A, Mirza R, Hepworth E, Chow A, Aydin S, Kuriya B.
ORA 2026
Cardiorenal–Metabolic Comorbidity and Therapy Eligibility in Rheumatoid Arthritis: Real-World Data from the OBRI
Movahedi M, Seebalack V, Cesta A, Akhavan P, Thorne C, Pope J, Kwok T, Lau A, Mirza R, Hepworth E, Chow A, Aydin S, Kuriya B.
ACR 2026
Cardiorenal–Metabolic Comorbidity and Therapy Eligibility in Rheumatoid Arthritis: Real-World Data from the OBRI
Movahedi M, Seebalack V, Cesta A, Akhavan P, Thorne C, Pope J, Kwok T, Lau A, Mirza R, Hepworth E, Chow A, Aydin S, Kuriya B.
Oral Glucocorticoid Use and Discontinuation Among JAK Inhibitors and Biologic DMARDs in Rheumatoid Arthritis: A Canadian Retrospective Cohort Study
Movahedi M, Cesta A, Akhavan P, Thorne C, Pope J, Kwok T, Lau A, Mirza R, Hepworth E, Chow A, Aydin S, Kuriya B, OBRI Investigators.
2025
CRA 2025
A cross-sectional study on predictors of COVID-19 infection, admission and effect of immunomodulating treatments in rheumatoid arthritis
Movahedi M, Hepworth E, Cesta A, Li X, Bombardier C, Aydin S, on behalf of OBRI Investigators.
Health Care Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study
Movahedi M, Cesta A, Li X, Tatangelo M, Bombardier C.
Hospitalizations, Emergency, Physician visits, Death, and chronic clinical conditions among rheumatoid arthritis patients with and without Herpes Zoster, a retrospective administrative data linked cohort study
Movahedi M, Cesta A, Li X, Tatangelo M, Bombardier C, on behalf of OBRI Investigators.
The Discontinuation and Effectiveness of Sequential Advanced Therapy in Rheumatoid Arthritis, a Real-World Data
Movahedi M, Cesta A, Li X, Kuriya B, Aydin A, Bombardier C, Akhavan P, on behalf of OBRI Investigators.
ORA 2025
Health Care Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study
Movahedi M, Cesta A, Li X, Tatangelo M, Bombardier C.
ACR 2025
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism: A Population-Based Cohort Study
Movahedi M, Cesta A, Akhavan P, Kendzerska T, Aydin S, Bombardier C, Kuriya B.
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of All-Cause Mortality and All-Cause Cancer: A Population-Based Cohort Study
Movahedi M, Cesta A, Akhavan P, Kendzerska T, Aydin S, Bombardier C, Kuriya B.
2024
CRA 2024
The association between disease activity, physical function and anti-rheumatic medication and all-cause mortality in patients with RA, Data from a Rheumatoid Arthritis Registry in Canada
Movahedi M, Cesta A, Li X, Kuriya B, Aydin S, Keystone E, Pope J, Bombardier C.
Influence of age and sex on disease trajectory in rheumatoid arthritis: Results from the Ontario Best Practices Research Initiative
Boyle J, Cesta A, Mously C, Li X, Kuriya B, Pope J, Keystone E, Bombardier C, Aydin S, Hofstetter C, Movahedi M, OBRI Investigators.
Improving Outcomes of Patient Living with Psoriatic Arthritis: Results from the Observational Best Practices Research Initiative-Psoriatic Arthritis (OBRI-PsA)
Chow A, Lau A, Soucy E, Movahedi M, Li X, Mously C, Cesta A, Thorne C, Ahluwalia V, Chandran V, Boyle J, Dhillon R, Chan J, Joshi R, Bombardier C, Aydin S.
Impact of anti-rheumatic treatment on the individual components of the ACR composite score in patients with rheumatoid arthritis: real-world data
Movahedi M, Choquette D, Coupal L, Keystone E, Bombardier C, Bessette L.
EULAR 2024
The association between disease activity, physical function and anti-rheumatic medication and all-cause mortality in patients with RA, Data from a Rheumatoid Arthritis Registry in Canada
Movahedi M, Cesta A, Li X, Kuriya B, Aydin S, Keystone E, Pope J, Bombardier C.
Influence of age and sex on disease trajectory in rheumatoid arthritis: Results from the Ontario Best Practices Research Initiative
Boyle J, Cesta A, Mously C, Li X, Kuriya B, Pope J, Keystone E, Bombardier C, Aydin S, Hofstetter C, Movahedi M, OBRI Investigators.
ORA 2024
Healthcare Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study
Movahedi M, Cesta A, Li X, Tatangelo M, Bombardier C.
Improving Outcomes of Patient Living with Psoriatic Arthritis: Results from the Observational Best Practices Research Initiative-Psoriatic Arthritis (OBRI-PsA)
Chow A, Lau A, Soucy E, Movahedi M, Li X, Mously C, Cesta A, Thorne C, Ahluwalia V, Chandran V, Boyle J, Dhillon R, Chan J, Joshi R, Bombardier C, Aydin S.
ACR 2024
Associations between disease activity, physical function and anti-rheumatic medications with all-cause mortality in rheumatoid arthritis (RA): Data from a Canadian RA Registry
Movahedi M, Cesta A, Li X, Kuriya B, Aydin S, Keystone E, Pope J, Bombardier C.
The Discontinuation and Effectiveness of Sequential Advanced Therapy in Rheumatoid Arthritis, a Real-World Data
Movahedi M, Cesta A, Li X, Kuriya B, Aydin S, Bombardier C, Akhavan P, on behalf of OBRI Investigators.
A cross-sectional study on predictors of COVID-19 infection, admission and mortality and effect of immunomodulating treatments in Rheumatoid Arthritis
Movahedi M, Hepworth E, Cesta A, Li X, Bombardier C, Aydin S, on behalf of OBRI Investigators.
Healthcare Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study
Movahedi M, Cesta A, Li X, Tatangelo M, Bombardier C.
Conference presentations are updated regularly
For a complete list of OBRI conference presentations or to inquire about upcoming presentations, contact us at Angela.Cesta@uhn.ca.
